News and research before you hear about it on CNBC and others. Claim your 1-week free trial for StreetInsider Premium here.
As an active cleanser, Nexodyn (R) AOS exhibits superior wound healing performance compared to standard of care
GENEVA, SWITZERLAND / ACCESSWIRE / September 30, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (“Relief“), a biopharmaceutical company seeking to provide patients with therapeutic relief from serious illnesses with high unmet needs, today announced that its wholly-owned subsidiary, APR Applied Pharma Research SA (“APR“), the reported data published in the peer review Wound Care Journal, indicating that the company’s Nexodyn (R) Acid Oxidation Solution (AOS), developed with APR’s proprietary Tehclo (R) technology, has been shown to be a very effective treatment in promoting healing of infected wounds or uninfected difficult to heal leg ulcers. The data also confirmed the safety and tolerability of Nexodyn (R).
Conducted by Robert Strohal, MD, Professor and Head of Department, Department of Dermatology, Federal Teaching University Hospital Feldkirch, Austria, and colleagues, the open-label randomized controlled MACAN study was conducted at two centers in Austria. A total of 50 patients were included, with infected or uninfected leg ulcers, difficult to heal, of different aetiology. Patients were treated for six weeks with Nexodyn (R) AOS or Standard of Care (SOC) dressings.
In the group of patients treated with Nexodyn (R) AOS, the wounds had a faster and more pronounced reduction in wound size than wounds in the SOC group. Additionally, compared to SOC, the treatment group showed a significantly higher percentage of complete healing of hard-to-heal ulcers at the end of the study period (32% vs. 8%, respectively). In addition, Nexodyn (R) has demonstrated its ability to significantly reduce wound pH (p
The MACAN study publication reconfirms the efficacy of Nexodyn (R) AOS, developed with our world-patented Tehclo (R) nanotechnology platform, against SOC, providing further evidence of its unique ability to dramatically reduce time healing, protect against infection risks and reduce clinical signs of local infection, “said Paolo Galfetti, CEO of APR and President of Relief Europe.” It is important to note that the study showed that Nexodyn (R) AOS, with its antimicrobial properties, is able to control infection as a stand-alone treatment and the reduction in pH in the wound bed is directly associated with healing. In addition, by restoring the prerequisites of the physiological healing process, the use of Nexodyn (R) AOS can significantly help restart chronic wound closure. Published results show that Nexodyn (R) AOS is not only not inferior to, but is, in fact, superior to standard of care for dressings, clearly establishing Nexodyn (R) AOS, as an important treatment for chronic wounds that are difficult to treat. “
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, added: “The marked improvement in wound healing reported in the MACAN study also bodes well for APR-TD011, developed with the same Tehclo (R) platform as Nexodyn (R) AOS, which is designed as a comprehensive treatment for patients with epidermolysis bullosa (EB) to prevent or reduce infections and inflammation of skin lesions through modulation of the microenvironment of the wound to promote faster physiological healing. APR TD-011 has received orphan drug designation and may become an important orphan drug treatment option for the approximately 250,000 EB patients worldwide. “
About Nexodyn (R) Acid Oxidizing Solution (OSA)
Nexodyn (R) Acid-Oxidizing Solution (AOS) is a Tehclo (R) product proven to jump-start the healing of blocked wounds by creating the ideal microenvironment to support the physiological healing process. A plethora of evidence and real-life experiences consistently show accelerated closure with reduced infection rates and less pain associated with the wound.
Nexodyn (R) AOS is a solution with three main characteristics: highly pure and stabilized hypochlorous acid (HClO> 95% of free chlorinated species), acidic pH (2.5 – 3.0) and high reduction-oxidation potential (ORP 1,000 – 1,200 mV). The product is a sprayable solution with auxiliary antimicrobial properties intended for use in the debridement, irrigation, cleansing and moistening of acute and chronic wounds (eg, diabetic foot ulcers, bedsores and vascular ulcers. ), post-surgical wounds, burns and other injuries. The product is certified in the European Union as a Class III medical device.
Relief primarily focuses on clinical stage programs based on molecules with a history of clinical trials and use in human patients or a strong scientific rationale. Relief’s primary drug candidate, RLF-100MT (aviptadil), a synthetic form of vasoactive intestinal peptide (VIP), is in advanced clinical trials in the United States for the treatment of respiratory impairment due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a collaboration and license agreement with Acer Therapeutics for the global development and commercialization of ACER-001. ACER-001 is a patented, taste-masked, immediate-release powder formulation of sodium phenylbutyrate (NaPB) for the treatment of urea cycle disorders and maple syrup disease. In addition, Relief’s recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH bring a diverse pipeline of commercialized and development-phase programs.
RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and listed in the United States on the OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.
RELIEF THERAPEUTICS Holding SA
Financial Director and Treasurer
FOR MEDIA / INVESTOR REQUESTS:
Rx communication group
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including the risks discussed in the documents filed by RELIEF THERAPEUTICS Holding SA with SIX, which could cause a material difference between the actual results, the situation financial, performance or achievements of RELIEF THERAPEUTICS Holding SA. future results, performances or achievements expressed or implied by these forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication on this date and does not undertake to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
THE SOURCE: Relief Therapeutics Holdings AG
See the source version on accesswire.com:
https://www.accesswire.com/666218/Reliefs-Subsidiary-APR-Applied-Pharma-Research-Reports-Data-Published-in-Journal-of-Wound-Care-Indicating-NexodynR-AOS-Highly-Effective- Treatment-to-support-the-healing-of-difficult-to-cure-leg ulcers